SWS Partners Acquires 17,458 Shares of DexCom, Inc. $DXCM

SWS Partners grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 45.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 55,560 shares of the medical device company’s stock after purchasing an additional 17,458 shares during the period. SWS Partners’ holdings in DexCom were worth $3,688,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in DXCM. Marshall Wace LLP raised its position in shares of DexCom by 260.7% in the second quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock valued at $333,630,000 after buying an additional 2,762,504 shares in the last quarter. Holocene Advisors LP acquired a new stake in DexCom during the third quarter worth approximately $163,964,000. CIBC Private Wealth Group LLC increased its stake in DexCom by 374.3% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after acquiring an additional 2,294,709 shares during the period. Federated Hermes Inc. increased its stake in DexCom by 82.1% during the 2nd quarter. Federated Hermes Inc. now owns 3,633,139 shares of the medical device company’s stock worth $317,137,000 after acquiring an additional 1,638,407 shares during the period. Finally, Vanguard Group Inc. raised its holdings in DexCom by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock valued at $3,327,897,000 after acquiring an additional 1,133,638 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DXCM. Piper Sandler reiterated an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target for the company in a research note on Tuesday, March 24th. BTIG Research reaffirmed a “buy” rating and set a $85.00 price objective on shares of DexCom in a research report on Monday, March 9th. Sanford C. Bernstein reissued an “outperform” rating and issued a $86.00 target price (up from $84.00) on shares of DexCom in a report on Friday, January 9th. Finally, Barclays restated an “underweight” rating and issued a $72.00 target price (up from $71.00) on shares of DexCom in a research report on Friday, February 13th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $86.50.

DexCom Trading Down 0.7%

Shares of DXCM opened at $62.37 on Thursday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The business’s fifty day moving average is $69.56 and its 200-day moving average is $67.34. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The firm has a market cap of $24.00 billion, a price-to-earnings ratio of 29.70, a PEG ratio of 1.22 and a beta of 1.55.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.03. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.DexCom’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.45 EPS. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $64.85, for a total value of $110,245.00. Following the completion of the transaction, the executive vice president owned 112,904 shares of the company’s stock, valued at approximately $7,321,824.40. This represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.